SCHEMBL30980775

CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1CCCOCCOCCNC(=O)NCCCC(CCCNC(=O)NCCOCCOCCC[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)(CCCNC(=O)NCCOCCOCCC[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)NC(=O)C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 13)

	gene	UniProt	supporting neighbours	confidence
▸	MAPK1	P28482	2/20	0.38

▸	ALDH1A1	P00352	2/20	0.35

▸	THRB	P10828	1/20	0.35

▸	MDK	P21741	1/20	0.35

▸	CD69	Q07108	1/20	0.33

▸	LGALS8	O00214	1/20	0.32

▸	LGALS3	P17931	1/20	0.32

▸	LGALS4	P56470	1/20	0.32

▸	OGA	O60502	1/20	0.32

▸	B4GALT1	P15291	1/20	0.32

▸	SMN1; SMN2	Q16637	1/20	0.31

▸	MEN1	O00255	1/20	0.31

▸	KMT2A	Q03164	1/20	0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30980709	0.86	MAPK1 (0.41)	MAPK1ALDH1A1THRBMDKCD69
SCHEMBL30980568	0.83	MAPK1 (0.38)	MAPK1ALDH1A1THRBMDKCD69
SCHEMBL30980620	0.82	HRAS (0.39)	LGALS8OGASMN1; SMN2
SCHEMBL30980512	0.82	MAPK1 (0.33)	MAPK1ALDH1A1THRBMDKCD69
SCHEMBL30980642	0.82	MAPK1 (0.43)	MAPK1ALDH1A1THRBMDKCD69
SCHEMBL30980649	0.81	MAPK1 (0.43)	MAPK1ALDH1A1THRBMDKCD69
SCHEMBL30980522	0.80	MAPK1 (0.43)	MAPK1ALDH1A1THRBMDKCD69
SCHEMBL30980773	0.79	MAPK1 (0.40)	MAPK1ALDH1A1THRBMDKCD69
SCHEMBL30980606	0.78	MAPK1 (0.47)	MAPK1ALDH1A1THRBMDKCD69
SCHEMBL30980757	0.78	MAPK1 (0.46)	MAPK1ALDH1A1THRBMDKCD69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-4651902-A2	ASGPR BINDING COMPOUNDS AND CONJUGATES	Lycia Therapeutics, Inc. (US)	2025-11-26	—	—	EP	disclosed
EP-4651901-A1	CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES	Lycia Therapeutics, Inc. (US)	2025-11-26	—	—	EP	disclosed
WO-2025035040-A1	LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES	LYCIA THERAPEUTICS, INC. (US)	2025-02-13	—	—	WO	disclosed
WO-2024155747-A2	ASGPR BINDING COMPOUNDS AND CONJUGATES	LYCIA THERAPEUTICS, INC. (US)	2024-07-25	—	—	WO	disclosed